NASDAQ:GLMD Galmed Pharmaceuticals (GLMD) Stock Price, News & Analysis $4.59 -0.04 (-0.86%) Closing price 09/9/2026 07:56 PM EasternExtended Trading$4.59 0.00 (0.00%) As of 09/9/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC Filings About Galmed Pharmaceuticals Stock (NASDAQ:GLMD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Galmed Pharmaceuticals alerts:Sign Up Key Stats Today's Range$3.82▼$4.6350-Day Range$3.83▼$4.9752-Week Range$3.29▼$13.20Volume302,067 shsAverage Volume52,894 shsMarket Capitalization$4.77 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Galmed Pharmaceuticals Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for metabolic and liver diseases. The company’s principal program centers on Aramchol, a synthetic fatty acid-bile acid conjugate designed to reduce liver fat accumulation and fibrosis in patients with nonalcoholic steatohepatitis (NASH). Galmed conducts translational research to validate its mechanism of action and advance its drug candidates through regulatory trials. In addition to Aramchol, Galmed maintains a pipeline of complementary small-molecule compounds aimed at modulating lipid metabolism and inflammatory pathways implicated in chronic liver disorders. The company leverages strategic partnerships for manufacturing and formulation development while pursuing regulatory approvals in key markets. Its clinical trial activities span North America and Europe, with trial sites designed to support potential future commercialization in regions where NASH represents a substantial unmet medical need. Founded in 2001 and headquartered in Tel Aviv, Israel, Galmed maintains corporate offices in the United States to facilitate interactions with regulatory agencies, clinical investigators and potential commercial partners. The company’s leadership team combines expertise in pharmaceutical development, hepatology and global commercialization strategy. Galmed Pharmaceuticals is publicly traded on the NASDAQ under the ticker symbol GLMD and remains committed to advancing therapies for patients suffering from progressive liver disease.AI Generated. May Contain Errors. Read More Galmed Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreGLMD MarketRank™: Galmed Pharmaceuticals scored higher than 25% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingGalmed Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageGalmed Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Galmed Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Galmed Pharmaceuticals is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Galmed Pharmaceuticals is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGalmed Pharmaceuticals has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Galmed Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.35% of the float of Galmed Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverGalmed Pharmaceuticals has a short interest ratio ("days to cover") of 0.35, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Galmed Pharmaceuticals has recently decreased by 47.27%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGalmed Pharmaceuticals does not currently pay a dividend.Dividend GrowthGalmed Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.51 News SentimentGalmed Pharmaceuticals has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.86 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Galmed Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest3 people have searched for GLMD on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Galmed Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Galmed Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders19.80% of the stock of Galmed Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions76.14% of the stock of Galmed Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Galmed Pharmaceuticals' insider trading history. Receive GLMD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Galmed Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GLMD Stock News HeadlinesGalmed Pharmaceuticals (NASDAQ:GLMD) Shares Cross Above 50-Day Moving Average - Here's WhySeptember 10 at 4:01 AM | americanbankingnews.comGalmed Pharma Rebrands To EoCene, Debuts EOCN Ticker As GI Expansion Accelerates; Stock UpSeptember 9 at 3:04 PM | rttnews.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.September 11 at 1:00 AM | Base Camp Trading (Ad)Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI InnovationSeptember 9 at 7:30 AM | prnewswire.com6 Biotech Stocks In Focus: Modular Medical, Galmed, Pro-Dex, Connect Biopharma & MoreSeptember 3, 2026 | rttnews.comGalmed Pharmaceuticals Shareholders Approve All Proposals at September 3 AGMSeptember 3, 2026 | tipranks.comGalmed Pharmaceuticals Ltd.: Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment TechnologyAugust 19, 2026 | finanznachrichten.deGalmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment TechnologyAugust 19, 2026 | prnewswire.comSee More Headlines GLMD Stock Analysis - Frequently Asked Questions How have GLMD shares performed this year? Galmed Pharmaceuticals' stock was trading at $6.0040 at the beginning of 2026. Since then, GLMD shares have decreased by 23.6% and is now trading at $4.59. How were Galmed Pharmaceuticals' earnings last quarter? Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) issued its quarterly earnings data on Wednesday, September, 2nd. The biopharmaceutical company reported ($2.86) earnings per share for the quarter, topping the consensus estimate of ($3.12) by $0.26. When did Galmed Pharmaceuticals' stock split? Shares of Galmed Pharmaceuticals reverse split before market open on Monday, May 15th 2023.The 1-15 reverse split was announced on Monday, May 15th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, May 15th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. When did Galmed Pharmaceuticals IPO? Galmed Pharmaceuticals (GLMD) raised $37 million in an initial public offering (IPO) on Thursday, March 13th 2014. The company issued 2,837,400 shares at $12.00-$14.00 per share. How do I buy shares of Galmed Pharmaceuticals? Shares of GLMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Galmed Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Galmed Pharmaceuticals investors own include Viking Therapeutics (VKTX), OPKO Health (OPK), SCYNEXIS (SCYX), Bristol Myers Squibb (BMY), Plug Power (PLUG), Sorrento Therapeutics (SRNE). Company Calendar Last Earnings9/02/2026Today9/11/2026Next Earnings (Estimated)11/25/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:GLMD CIK1595353 Webwww.galmedpharma.com Phone(723) 693-8448Fax972-3693-8447Employees20Year Founded2000Profitability EPS (Trailing Twelve Months)($15.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.31 million Net MarginsN/A Pretax MarginN/A Return on Equity-73.68% Return on Assets-60.88% Debt Debt-to-Equity RatioN/A Current Ratio4.16 Quick Ratio4.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$23.04 per share Price / Book0.20Miscellaneous Outstanding Shares1,040,000Free Float836,000Market Cap$4.77 million OptionableNot Optionable Beta0.67 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (NASDAQ:GLMD) was last updated on 9/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galmed Pharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galmed Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GLMD Stock Alerts